Four extra COVID-19 vaccines are being developed and their producers could strategy the drug controller for emergency use authorisation, the Health Ministry stated on Tuesday.
Addressing a press briefing, Union Health Secretary Rajesh Bhushan stated Zydus Cadila, Sputnik V, Biological E and Gennova are different vaccines which might be at present in a complicated medical trials stage in India.
“In the coming days you may see some of these vaccines too approaching the drug controller for emergency use authorisation,” Mr Bhushan stated.
Elaborating additional, Mr Bhushan stated Zydus Cadilla accomplished Phase 2 medical trials of its coronavirus vaccine in December and has been granted approval for Phase 3.
Similarly, Phase 2 medical trials of Russia’s Sputnik-V COVID-19 vaccine have additionally concluded, and Phase Three trials are being carried out by its Indian companion Dr Reddy’s laboratories, he stated.
In the case of Biological E, Mr Bhushan stated the Phase 1 medical trials of its vaccine began in December and Phase 2 is anticipated to start in March.
Gennova’s M-RnA-based COVID-19 vaccine is at present in Phase 1 with Phase 2 medical trials prone to start in March of this yr, he stated.
Mr Bhushan stated Pfizer-BioNTech is offered at Rs 1,431 per dose, Moderna at Rs 2,348 to Rs 2,715 per dose, Sinopharm at Rs 5,650 per dose, Sinovac Biotech at Rs 1,027 per dose, Novavax at Rs 1,114 per dose, Gamaleya Centre at lower than Rs 734 per dose and Johnson and Johnson at Rs 734 per dose.
All these vaccines, besides the one by Pfizer, may be saved between 2-Eight levels Celsius. Pfizer must be saved at minus 70 levels Celsius, he added.
India will launch its COVID-19 vaccination drive from January 16 with precedence to almost three crore healthcare and frontline employees.